Highlights Immunovia AB

Stocks

IMMNOV

SE0006091997

Advanced Medical Equipment & Technology

Delayed Nasdaq Stockholm Other stock markets 12:00:00 2026-06-11 pm EDT			5-day change	1st Jan Change
0.1780 ^SEK	-2.84%		-9.28%	-21.59%

Jun. 10	Immunovia: Published study bolsters evidence for PancreaSure	FW
Jun. 10	Immunovia Publishes Final Affirm Study Results in Journal of Clinical Oncology Confirming Strong Diagnostic Performance of Pancreasure	CI

Highlights

Jun. 10	Immunovia Publishes Final Affirm Study Results in Journal of Clinical Oncology Confirming Strong Diagnostic Performance of Pancreasure	CI
May. 07	Immunovia Q1 operating loss at SEK 18.4 mln	RE
May. 07	Immunovia AB Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
May. 05	Immunovia AB Launches Assure Registry To Evaluate Real-World Clinical Impact Of Pancreasure In High-Risk Pancreatic Cancer Surveillance	CI
Feb. 24	Immunovia AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025	CI
Jan. 20	Immunovia board withdraws reverse share split proposal, cancels meeting	RE
Jan. 19	Immunovia AB Receives State Regulatory Approval for Pancreasure in California and Initiates Commercial Rollout	CI
Jan. 19	Immunovia Wins Approval for PancreaSure Test in US	MT
Jan. 19	Immunovia gets state regulatory approval for Pancreasure in California	RE
Nov. 26	Immunovia AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
Nov. 26	Immunovia Q3 oper loss at SEK 25.5 mln	RE
25-10-27	Immunovia AB Announces Acceptance of Oral Plenary Presentation at American College of Gastroenterology 2025 Annual Scientific Meeting	CI
25-09-24	Immunovia AB Announces Results from Affirm	CI
25-09-15	Immunovia Announces its PancreaSure Test Will Be Offered to Patients in Inova Schar Cancer's High-Risk Surveillance Program	CI
25-09-02	Immunovia Launches the PancreaSure Test for Early Detection of Pancreatic Cancer in High-Risk Individuals	CI
25-08-28	Immunovia AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
25-08-28	Immunovia Q2 operating loss SEK 20.1 mln	RE
25-08-19	Immunovia Sets US Launch Date for Pancreatic Cancer Test	MT
25-08-19	Immunovia Set to Launch PancreaSure in the US on September 2	CI
25-06-09	Immunovia's Model Development Study Publishes in Cancers	CI
25-06-04	Immunovia Announces New Clinical Validation Study in Partnership with Leiden University Medical Center	CI
25-05-14	Immunovia AB Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
25-05-07	Immunovia AB Announces Clinical Validation Study Results in Digestive Disease Week	CI
25-03-24	Immunovia Provides Further Positive Data from the Verifi Study of Its Next-Generation Pancreatic Cancer Test	CI
25-03-19	Immunovia Announces Another Successful Clinical Validation of Its Next-Generation Pancreatic Cancer Test	CI